US2012064066A1PendingUtilityA1

Monoclonal Antibodies to Hepatocyte Growth Factor

55
Assignee: KIM KYUNG JINPriority: Apr 18, 2003Filed: Jun 14, 2011Published: Mar 15, 2012
Est. expiryApr 18, 2023(expired)· nominal 20-yr term from priority
Inventors:Kyung Jin KimYi-Chi Su
A61P 43/00A61P 35/00A61P 35/04A61P 1/16C07K 2317/76A61K 2039/505G01N 2333/4753C07K 2317/92C07K 16/22C07K 2317/73A61K 39/395C07K 16/00
55
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention is directed toward a neutralizing monoclonal antibody to hepatocyte growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A monoclonal antibody (mAb) that binds and neutralizes human Hepatocyte Growth Factor (HGF). 
     
     
         2 . The mAb of  claim 1  which is chimeric. 
     
     
         3 . The mAb of  claim 1  which is humanized. 
     
     
         4 . The mAb of  claim 1  which is human. 
     
     
         5 . The mAb of  claim 1  which inhibits binding of HGF to cMet by at least 50%. 
     
     
         6 . The mAb of  claim 1  which inhibits HGF-induced scattering of Madin-Darby canine kidney cells. 
     
     
         7 . The mAb of  claim 1  which inhibits HGF-induced angiogenesis. 
     
     
         8 . The mAb of  claim 1  which neutralizes all biological activities of HGF. 
     
     
         9 . The mAb of  claim 1  which inhibits growth of a human tumor xenograft in a mouse. 
     
     
         10 . The mAb of  claim 9  which completely inhibits growth of a human tumor xenograft in a mouse. 
     
     
         11 . The mAb of  claim 1  which is a Fab or F(ab′) 2  fragment or single-chain antibody. 
     
     
         12 . The mAb of  claim 1  which specifically binds HGF with a binding affinity of at least 10 8  M −1 . 
     
     
         13 . A chimeric or humanized L2G7 mAb. 
     
     
         14 . An antibody that competes for binding to human HGF with an antibody of  claim 13 . 
     
     
         15 . A cell line producing a mAb of  claim 1 . 
     
     
         16 . A pharmaceutical composition comprising a mAb of  claim 13 . 
     
     
         17 . A method of treating cancer in a patient comprising administering to the patient a pharmaceutical composition comprising a neutralizing anti-HGF mAb. 
     
     
         18 . A method of  claim 17  wherein said cancer is glioblastoma. 
     
     
         19 . The method of  claim 17  wherein said mAb is a chimeric or humanized L2G7 mAb.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.